Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HCW Biologics (HCWB) Equity Average (2020 - 2025)

HCW Biologics (HCWB) has disclosed Equity Average for 6 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average rose 86.73% year-over-year to -$1.1 million, compared with a TTM value of -$1.1 million through Sep 2025, up 86.73%, and an annual FY2024 reading of $3.3 million, down 86.85% over the prior year.
  • Equity Average was -$1.1 million for Q3 2025 at HCW Biologics, up from -$4.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $52.6 million in Q4 2021 and bottomed at -$21.6 million in Q2 2021.
  • Average Equity Average over 5 years is $16.0 million, with a median of $15.4 million recorded in 2021.
  • The sharpest move saw Equity Average skyrocketed 399.85% in 2021, then crashed 452.91% in 2025.
  • Year by year, Equity Average stood at $52.6 million in 2021, then decreased by 23.97% to $40.0 million in 2022, then plummeted by 53.33% to $18.7 million in 2023, then crashed by 144.84% to -$8.4 million in 2024, then surged by 87.1% to -$1.1 million in 2025.
  • Business Quant data shows Equity Average for HCWB at -$1.1 million in Q3 2025, -$4.3 million in Q2 2025, and -$7.7 million in Q1 2025.